SRR9879281
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.460
- INTERFERON_ALPHA_RESPONSE+0.390
- MYC_TARGETS_V2+0.390
- MTORC1_SIGNALING+0.370
- UNFOLDED_PROTEIN_RESPONSE+0.350
- ANDROGEN_RESPONSE+0.340
- GLYCOLYSIS+0.330
- OXIDATIVE_PHOSPHORYLATION+0.330
- FATTY_ACID_METABOLISM+0.320
- ADIPOGENESIS+0.270
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.330
- E2F_TARGETS-0.320
- G2M_CHECKPOINT-0.290
- APICAL_SURFACE-0.280
- ANGIOGENESIS-0.250
- APOPTOSIS-0.250
- COAGULATION-0.250
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.240
- TGF_BETA_SIGNALING-0.240
- APICAL_JUNCTION-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-ADCB-TTM1-A-1-1-R-A742-41 | — | C | 0.812 |
| 2 | TCGA-C8-A133-01A-32R-A12D-07 | — | B | 0.776 |
| 3 | SRR6013565 | — | cohortA4 | 0.770 |
| 4 | TCGA-OR-A5LM-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.752 |
| 5 | SRR8518413 | — | F | 0.740 |
| 6 | BS_G3RJTBZD | high-grade glioma | — | 0.738 |
| 7 | TCGA-BH-A0HO-01A-11R-A034-07 | — | B | 0.734 |
| 8 | TCGA-A8-A07P-01A-11R-A00Z-07 | — | B | 0.733 |
| 9 | TCGA-BH-A1FG-01A-11R-A13Q-07 | — | B | 0.731 |
| 10 | ee24b470-4509-4687-a91e-6d2b967336b9 | — | — | 0.730 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.460 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.390 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.390 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.370 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.350 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.340 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.330 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.330 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.320 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.270 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.270 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.250 | Idelalisib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.170 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.170 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.170 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.160 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.110 | Inavolisib | — uncovered |